Amgen Announces Departure of David M. Reese: Transforming Leadership Structure

In a significant move within the biotechnology sector, Amgen (NASDAQ: AMGN) has announced the retirement of David M. Reese, M.D., its Executive Vice President and Chief Technology Officer, effective June 30, 2026. Reese, who joined the company in 2005 and has held pivotal roles, will leave a lasting legacy in the realm of innovative medicine development.

Dr. Reese started his journey at Amgen focusing on clinical development in oncology and rose to lead the Research and Development (R&D) team from 2018 to 2023. Under his stewardship, the company achieved numerous approvals for groundbreaking medicines and biosimilars, while also ensuring a robust pipeline of new therapies. As the inaugural Chief Technology Officer, he was a pioneer in integrating technology and artificial intelligence into Amgen's R&D processes.

Robert A. Bradway, Chairman and CEO of Amgen, emphasized Reese's foresight in recognizing the transformative potential of technology and biology within the industry. He noted, “Dave recognized early the impact that advances in biology and technology would have on our industry and helped lead Amgen through that shift.” This acknowledgment highlights how Reese's leadership has been foundational in positioning the company for future advancements in healthcare.

Amgen is now embarking on a strategic evolution to align its operations more closely with the convergence of biology and technology. This initiative called